More than one-third of tumors sequenced carried a high mutation burden.
The nomogram proved more accurate than TNM staging for predicting 3-year and 5-year overall survival.
Cyberattacks on health care organizations may not be fully preventable, but there are ways to limit their impact on cancer care.
The 12-month progression-free survival rate was 35.9% with sunitinib and 18.9% with placebo.
The approval was based on data from the phase 3 COSMIC-311 study.
The risk of recurrence varied by patient age, tumor size, and number of foci.
Response rates were highest with MIBG plus vorinostat.
Patients with stage II or IV disease did not fare as well as patients with stage I or III disease.
The rCOJEC regimen was less toxic than the MSKCC-N5 regimen.
Response endpoints were not strongly correlated with overall survival at the trial level.
The overall survival rate at 1 year was 86% with vandetanib and 70% with cabozantinib.
Patients with parathyroid carcinoma after localized resection for a presumed benign indication should undergo close monitoring for recurrence rather than radical surgery.
Children treated for neuroblastoma developed myeloid neoplasms with specific platinum chemotherapy-associated mutation signatures.
The response rate was higher for patients with pancreatic NETs than for those with gastrointestinal NETs.
A statement recommends including cancer patients and survivors in COVID-19 vaccine trials.
In a phase 2 trial, lenvatinib produced an objective response rate of about 3%.
Patient advocate Marlena Murphy provides a patient’s perspective on GRASP.
GRASP co-founder Julia Maués explains how the initiative came about and reveals plans for the future.
New guidelines recommend using the full approved doses of immunotherapy and targeted therapies for patients with cancer and obesity.
Cabozantinib significantly improved progression-free survival, and there was a trend toward improved overall survival.
Researchers identified risk factors for distant metastasis in sporadic and hereditary medullary thyroid cancer.
Researchers found that the therapy did not improve EFS or OS in high-risk patients and also led to an increase in toxic side effects.
The designation is supported by data from the randomized, double-blind, placebo-controlled phase 3 COSMIC-311 study.
Investigators tested the hypothesis that greater exposure to light at night (LAN) is associated with an increased risk for thyroid cancer by studying artificial outdoor LAN measured by satellite imagery in relation to thyroid cancer.
The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.